Payment overview · 2025
General Payments
$46,385.52
111 reported records · 14 companies
Healthcare provider profile · identity verified
Sathya Bhandari, M.D.
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation|Pain Medicine · FLOWER MOUND, TX · NPI 1356419980
Verified facts
What the public records show
CMS Open Payments records show Sathya Bhandari, M.D. received $46,385.52 in general payments during 2025 across 111 reported records.
Boston Scientific Corporation accounted for 98.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Botox by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45,571.19 | 98.2% | 73 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $142.19 | 0.3% | 8 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $138.99 | 0.3% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $94.76 | 0.2% | 5 | 2025 |
| Spinal Simplicity, LLC | Unresolved — no canonical attribution shown | $71.91 | 0.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.64 | 0.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.67 | 0.1% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $52.59 | 0.1% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $47.66 | 0.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.42 | 0.1% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.31 | 0.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.31 | 0.1% | 2 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $17.54 | 0.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.34 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,250.00 | 25 |
| Travel and Lodging | $3,534.59 | 17 |
| Food and Beverage | $2,600.93 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $31,804.33 | 43 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $8,257.48 | 15 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $5,202.14 | 10 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $231.20 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $138.99 | 3 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $94.76 | 5 | 2025 |
Source payment records
|
|||||
| HA MINUTEMAN G3-R Normalized: ha minuteman g3 r |
Device | Spinal Simplicity, LLC | $71.91 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.64 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.64 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $54.67 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $31.34 | 2 | 2025 |
Source payment records
|
|||||
| Intracept RF Probe Normalized: intracept rf probe |
Device | Boston Scientific Corporation | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| MILD DEVICE KIT Normalized: mild device kit |
Device | Stryker Corporation | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 437 | 91 |
| Gabapentin | Gabapentin | 104 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Pregabalin | Pregabalin | 41 | 22 |
| Celecoxib | Celecoxib | 38 | 15 |
| Tramadol Hcl | Tramadol Hcl | 32 | 16 |
| Methadone Hcl | Methadone Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Buprenorphine | Buprenorphine | 23 | suppressed |
| Prednisone | Prednisone | 21 | 20 |
| Baclofen | Baclofen | 19 | 13 |
| Alprazolam | Alprazolam | 17 | suppressed |
| Botox | Onabotulinumtoxina | 17 | suppressed |
| Etodolac | Etodolac | 17 | 12 |
| Cephalexin | Cephalexin | 16 | 16 |
| Fentanyl | Fentanyl | 14 | suppressed |
| Diazepam | Diazepam | 13 | 13 |
| Lorazepam | Lorazepam | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46,385.52 · 111 records | Boston Scientific Corporation | BOTOX, Clinical Trial Product, ELYXYB - CELECOXIB, Evoke, General - Pain Management, General - Therapies, HA MINUTEMAN G3-R, HORIZANT, Intracept, Intracept RF Probe, MILD DEVICE KIT, NURTEC ODT, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PROCLAIM, QULIPTA, TONMYA, UBRELVY, VYEPTI, WaveWriter Alpha Prime 16, XTAMPZA, ZAVZPRET, ZTLido | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error